NEWS

Columbus Venture Partners successfully completes the sale of Syngoi Technologies to U.S.-based Artis BioSolutions Read More
Accipiter Biosciences announces a $12.7M seed round to design protein therapies for complex diseases Read More
ARTHEx Biotech extends Series B to $87M to advance its therapy for Myotonic Dystrophy Type 1 Read More
Columbus Venture Partners increases its commitment to Integra Therapeutics with €10.7M raise Read More
Highlight Therapeutics and CNIO launch their seventh clinical trial in advanced skin cancer Read More
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness Read More
Quibim Announces a $50 Million Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers Read More
Artax Biopharma achieves clinical validation of first-in-class, oral,  Nck modulator AX-158 for autoimmune disease in phase 2a study Read More
Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy Read More
Buenavista Equity Partners, together with Columbus Venture Partners, completes first €100mn closing for its healthcare fund Read More
Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer Read More
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1) Read More
Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases  Read More
Cocoon Bioscience has inaugurated the first industrial production plant for recombinant proteins using living bioreactors in Euskadi, Spain Read More
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science Read More
Integra Therapeutics receive up to €10.5 million from European Commission for its FiCAT advanced therapies platform Read More
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain Read More
Syngoi Technologies Expands Synthetic DNA Manufacturing Capacity Following Series B Investment Led by Columbus Venture Partners Read More
1 2 3 8
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.